Status:
TERMINATED
SNAP 25 Gene Study
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
UBC Human Early Learning Partnership (HELP)
Conditions:
Attention-Deficit/Hyperactivity Disorder
Eligibility:
All Genders
6+ years
Brief Summary
To enhance our capacity to correctly choose the appropriate medication for ADHD patients on the first try based on the presence of a particular variant of a gene that could be identified on a laborato...
Detailed Description
Previous research has demonstrated that while 75% of patients respond to any stimulant, of those who do not 33% will respond to a stimulant of the other class. Based on previous research correlating i...
Eligibility Criteria
Inclusion
- Patients will be male or female outpatients who are at least 6 years of age (there is no upper age limit)
- Patients must meet DSM-IV criteria for ADHD
- Patients and parents/guardians must have a degree of understanding sufficient to be able to communicate suitably with the investigator and study coordinator
- Patients must have tolerated the drug at therapeutic doses, but have shown a true lack of improvement in symptoms
- Must have shown clinically significant superiority in improvement in ADHD symptoms on amphetamine relative to MPH.
Exclusion
- Must not have a true allergy to methylphenidate or amphetamines
- Must not have a history of serious adverse reactions to methylphenidate
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00885560
Start Date
July 1 2006
End Date
July 1 2010
Last Update
September 18 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Provincial ADHD Program, BC Children's & Women's Health Centre
Vancouver, British Columbia, Canada